Avalyn Pharma Inc. Common Stock (AVLN)
Avalyn Pharma Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $25.60, down 0.12% on the session, giving a market capitalisation of $1.13B. On trailing twelve-month figures it carries a trailing P/E of -19.84, a net margin of 0.0%. Its beta of -1.13 implies it has historically moved less than the broad market.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Avalyn Pharma Inc. Common Stock is most often compared with the following Healthcare names: